BioWorld

April 25, 2003

Genzyme Wins FDA Approval For Fabry's Disease Treatment

Genzyme General received FDA approval of the orphan drug Fabrazyme, an enzyme replacement therapy for a rare, genetic disorder called Fabry's disease. (BioWorld Today) Read More

High Revenues Drive Earnings Growth At Biotech Bellwethers

Coated Magnetic Beads Take Over Dendritic Cell's Flagging Down Of Invasive Antigens For Destruction

FDA Clears Path For Phase III; NeoRx Stock Soars On News

Correction

Thompson Pushes Administration Initiatives In Science Forum Talk

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Dec. 11, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 11, 2025.

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

Illustration of head with maze that is missing parts

CTAD 2025: The challenges of combination therapies for dementia

BioWorld Science

At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...

DEE-lightful: Praxis’ phase II results allow stock to flex its muscle

BioWorld

Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...